Subject Sera

Stage of Disease

Rationale for Inclusion

1

D2

Had history of bone metastases, resolved on androgen deprivation therapy, patient went off androgen deprivation, and disease free for 5 years

2

T1C

PSA rose to 2.0 ng/mL one year after prostatectomy, then declined to undetectable levels without treatment

3

D3

Known serum antibodies specific for HER-2/neu

4

D3

Known serum antibodies specific for HER-2/neu

5

T1C

Known serum antibodies specific for PSA and PAP

6

T1C

PSA rose to 1.5 ng/mL after prostatectomy, then declined to undetectable levels without treatment. History of autoimmune thyroiditis and pernicious anemia.

7

D3

Known serum antibodies specific for HER-2/neu

8

D3

Known serum antibodies specific for HER-2/neu

9

T1C

Known serum antibodies specific for HER-2/neu

10

D2

Received 8 months of androgen deprivation therapy for bone metastatic disease. PSA decreased to undetectable levels for four years subsequently

11

D2

History of autoimmune myopathy at time of diagnosis

12

T1C

PSA increased to 3.4 ng/mL after surgery, then subsequently declined without treatment

13

D3

On androgen deprivation therapy with rise, and then subsequent decline, in serum PSA

14

T1C

Longstanding history of prostatitis

15

D3

Advanced disease, not on chemotherapy

16

T1C

Early stage disease, pre-treatment

17

D3

Advanced disease, not on chemotherapy

18

T1C

Early stage disease, pre-treatment

19

D3

Advanced disease, not on chemotherapy

20

T1C

Known low-titer serum antibodies specific for PSA

21

D3

Advanced disease, not on chemotherapy

22

T1C

Known serum antibodies specific for p53